A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients . Clinics [Internet]. 2016 Oct. 1 [cited 2024 May 18];71(10):586-92. Available from: https://revistas.usp.br/clinics/article/view/122233